Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells

Antiviral Therapy

Volumn 8, Issue 5, 2003, Pages 463-470

  Walker, Ulrich A ^a   Venhoff, Nils ^a   Koch, Evo C ^a   Olschewski, Manfred ^a   Schneide, Josef ^a   Setzer, Bernhard ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYCLOOXYGENASE 2; DIDANOSINE; LACTIC ACID; LAMIVUDINE; LIPID; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; URIDINE; ZALCITABINE;

ARTICLE; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MITOCHONDRION; PRIORITY JOURNAL; PROPHYLAXIS; SYNTHESIS;

ANTI-HIV AGENTS; CYCLOOXYGENASE 2; DNA, MITOCHONDRIAL; ELECTRON TRANSPORT COMPLEX IV; HEPATOCYTES; HUMANS; ISOENZYMES; LACTATES; LIPID METABOLISM; MEMBRANE PROTEINS; MITOCHONDRIA; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REVERSE TRANSCRIPTASE INHIBITORS; TUMOR CELLS, CULTURED; URIDINE; ZALCITABINE;

EID: 0242300115     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lewis W & Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nature Medicine 1995; 1:417-422.
2. Brinkman K, Smeitink JA, Romijn JA & Reiss P. Mitochondrial toxicity induced by nucleoside analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
3. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clinical Therapeutics 2000;22:685-708.
4. Walker UA, Setzer B & Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16:2165-2173.
5. Lambert JS, Seidlin M, Reichman RC, Plank CS, Laverty M, Morse GD, Knupp C, McLaren C, Pettinelli C & Valentine FT. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A Phase I trial. New England Journal of Medicine 1990; 322:1333-1340.
6. Morris AA, Taanman JW, Blake J, Cooper JM, Lake BD, Malone M, Love S, Clayton PT, Leonard JV & Schapira AH. Liver failure associated with mitochondrial DNA depletion. Journal of Hepatology 1998; 28:556-563.
7. Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, Schaeffer A & Zafrani ES. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. Journal of Hepatology 1999; 30:156-160.
8. Gerard Y, Maulin L, Yazdanpanah Y, Tribonniere X, Amiel C, Maurage CA, Robin S, Sablonniere B, Dhennain C & Mouton Y. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000; 14:2723-2730.
9. Brinkman K, Vrouenraets S, Kauffman R, Weigel H & Frissen J. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS 2000; 14:2801-2802.
10. Walker UA & Byrne E. The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Acta Neurologica Scandinavica 1995; 92:273-280.
11. de la Asuncion JG, del Olmo ML, Sastre J, Pallardo FV & Vina J. Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver. Hepatology 1999; 29:985-987.
12. Fouty B, Frerman F & Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 1998; 352:291-292.
13. Venhoff N, Setzer B, Lebrecht D & Walker UA. Dietary supplements in the treatment of NRTI-related mitochondrial toxicity. AIDS 2002; 16:800-802.
14. Bodnar AG, Cooper JM, Leonard JV & Schapira AH. Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication. Biochemical Journal 1995; 305:817-822.
15. Keilbaugh SA, Hobbs GA & Simpson MV. Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2′,3′-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate. Molecular Pharmacology 1993; 44:702-706.
16. Sommadossi JP, Carlisle R, Schinazi RF & Zhou Z. Uridine reverses the toxicity of 3′-azido-3′-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrobial Agents & Chemotherapy 1988; 32:997-1001.
17. Walker UA, Bickel M, Lütke Volksbeck SI, Ketelsen UP, Schofer H, Setzer B, Venhoff N, Rickerts V & Staszewski S. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2002; 29:117-121.
18. Birkus G, Hitchcock MJ & Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrobial Agents & Chemotherapy 2002; 46:716-723.
19. Attardi G, Yoneda M & Chomyn A. Complementation and segregation behavior of disease-causing mitochondrial DNA mutations in cellular model systems. Biochimica et Biophysica Acta 1995; 1271:241-248.
20. Löffler M, Jöckel J, Schuster G & Becker C. Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Molecular & Cellular Biochemistry 1997; 174:125-129.
21. Calabresi P, Falcone A, St Clair MH, Wiemann MC, Chu SH & Darnowski JW. Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity. Blood 1990; 76:2210-2215.
22. Medina DJ, Tsai CH, Hsiung GD & Cheng YC. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrobial Agents & Chemotherapy 1994; 38:1824-1828.
23. Setzer B, Schlesier M, Thomas AK & Walker UA. Immunosuppressive effect of mtDNA-depletion by d-drugs in healthy human-lymphocytes. Antiviral Therapy 2003; 8:L43.
24. Silva HT, Cao W, Shorthouse R & Morris RE. Mechanism of action of leflunomide: in vivo uridine administration reverses its inhibition of lymphocyte proliferation. Transplantation Proceedings 1996; 28:3082-3084.
25. Leyva A, van Groeningen CJ, Kraal I, Gall H, Peters GJ, Lankelma J & Pinedo HM. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Research 1984; 44:5928-5933.
26. van Groeningen CJ, Leyva A, Kraal I, Peters GJ & Pinedo HM. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treatment Reports 1986; 70:745-750.
27. van Groeningen C, Peters G, Nadal J, Leyva A, Gall H & Pinedo H. Phase I clinical and pharmacokinetics study of orally administered uridine. Proceedings of the AACR 1987; 28:195.
28. Bhalla KN, Li GR, Grant S, Cole JT, MacLaughlin WW & Volsky DJ. The effect in vitro of 2′-deoxycytidine on the metabolism and cytotoxicity of 2′,3′-dideoxycytidine. AIDS 1990; 4:427-431.
29. Bhalla K, Birkhofer M, Li GR, Grant S, MacLaughlin W, Cole J, Graham G & Volsky DJ. 2′-Deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3′-azido-3′ -deoxythymidine with preservation of antiretroviral activity. Blood 1989; 74:1923-1928.
30. Falcone A, Darnowski JW, Ruprecht RM, Chu SH, Brunetti I & Calabresi P. Different effect of benzylacyclouridine on the toxic and therapeutic effects of azidothymidine in mice. Blood 1990; 76:2216-2221.
31. de Miranda P, Good SS, Yarchoan R, Thomas RV, Blum MR, Myers CE & Broder S. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clinical Pharmacology & Therapeutics 1989; 46:494-500.
32. Walker UA, Koch E, Venhoff N, Klinker H, Langman P, Zilly M, Schneider J & Setzer B. Uridine prevents and treats mtDNA depletion by NRTI pyrimidine analogues and fully restores mitochondrial function. Antiviral Therapy 2003; 8:L17.